Patient-Reported Outcomes (Pros) Of Cemiplimab Vs Chemotherapy In Advanced Non-Small Cell Lung Cancer (Ansclc): EMPOWER-Lung 1 Histology Subgroups

Sezer, A.Kilickap, S.Gumus, M.Bondarenko, I.Ozguroglu, M.Gogishvili, M.He, X.Gullo, G.Rietschel, P.Quek, R.2023-01-022023-01-0220220923-7534https://reader.elsevier.com/reader/sd/pii/S092375342203157X?token=CE440C703142DFD2F8552550E5FFE69B6C4BADA16CE67888407EC9305C61FAC843557A9FCF93829AF385621391C51EF6&originRegion=eu-west-1&originCreation=20230102074310http://hdl.handle.net/11727/8489enginfo:eu-repo/semantics/openAccessPatient-Reported Outcomes (Pros) Of Cemiplimab Vs Chemotherapy In Advanced Non-Small Cell Lung Cancer (Ansclc): EMPOWER-Lung 1 Histology SubgroupsconferenceObject33710891089000866211601445